Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Lodz – page 53

1 026 clinical trials in Lodz, Poland across 18 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Lodz at a glance
1 026
clinical trials
  • Research sites18
Type of trial
Recruitment status
Quick filters

1 026 trials in Lodz

Open in trial search

Non-small cell lung cancer

Not recruiting

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic lymphocytic leukaemia+3

Not recruiting

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Conjunctivitis allergic

Not recruiting

Study of bilastine for effectiveness, safety and quality of life in children aged 6 to 12 years with allergic rhinoconjunctivitis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Bilastine
  • Sponsor:A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Dementia Alzheimer's type

Not recruiting

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis

Not recruiting

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tuvusertib
  • Sponsor:Merck Healthcare KGaA

Obesity+1

Not recruiting

A study testing maridebart cafraglutide for weight loss in adults with overweight or obesity, with or without type 2 diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Type 2 diabetes mellitus

Not recruiting

Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus

Not recruiting

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Duchenne muscular dystrophy

Not recruiting

Study of SAT-3247 Compared to Placebo for Patients with Duchenne Muscular Dystrophy Who Can Walk

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:SAT-3247 oxalate
  • Sponsor:Satellos Bioscience Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Lodz

What the registry says about research in the country

01 Respiratory Research

Ongoing clinical trials focusing on respiratory viral infections and preventive vaccines, particularly targeting RSV and influenza in older adults. Studies evaluate vaccine efficacy and immune responses to protect against severe respiratory diseases.

  • RSV and Influenza Prevention
  • Vaccine Immunogenicity
  • COPD Management

Multiple studies assess combination vaccines and co-administration strategies to enhance protection against multiple respiratory pathogens.

02 Dermatological Studies

Innovative research examining treatments for plaque psoriasis and related conditions. Trials investigate novel therapeutic approaches including oral medications and biological treatments for moderate to severe cases.

  • Psoriasis Treatment
  • Hidradenitis Suppurativa
  • Inflammatory Skin Conditions

Studies focus on measuring improvement in disease severity and quality of life outcomes for patients.

03 Immunology and Vaccines

Comprehensive research on meningococcal and pneumococcal vaccines, with special attention to pediatric populations. Studies evaluate safety profiles and immune responses across different age groups.

  • Pediatric Vaccinations
  • Immune Response Assessment
  • Preventive Medicine

Trials incorporate multiple age cohorts from infants to adolescents, ensuring comprehensive vaccine effectiveness data.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.